2018 UK Tumor Marker Testing Market Shares, Segmentation Forecasts, Competitive Landscape, Innovative Technologies, Latest Instrumentation, Opportunities for Suppliers

Highlights

  • Comprehensive 575-page analysis of the UK tumor marker testing market.
  • Major issues pertaining to the UK laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next five years.
  • Mortality statistics and scientific views on the etiology of major types of cancer, e.g., lung, colorectal, breast, prostatic, pancreatic, leukemia, lymphoma, gastrointestinal, bladder, liver, ovarian, testicular, oral, skin and others.
  • Five-year test volume and sales forecasts over for 40 tumor marker performed in UK hospitals, commercial laboratories and physician offices.
  • Placements and installed base of automated and semi-automated analyzers used for tumor marker testing.
  • Current instrumentation technologies and feature comparison of leading analyzers.
  • Sales and market shares of leading suppliers.
  • Emerging diagnostic technologies and their potential market applications.
  • Product development opportunities.
  • Profiles of current and emerging suppliers, including their sales, market shares, product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements and business strategies.
  • Business opportunities and strategic recommendations for suppliers.
I. Introduction
II. Worldwide Market Overview
1. Market Overview
2. Worldwide Market Structure
3. Worldwide Market Size and Growth
III. Major Product Development Opportunities
A. Reagent Kits and Test Systems/Panels
B. Instrumentation
C. Computers, Software and Automation
D. Auxiliary Products
IV. Design Criteria for Decentralized Testing Products
V. Alternative Market Penetration Strategies
A. Internal Development
B. Collaborative Arrangements
C. University Contracts
D. Distribution Strategies
VI. Potential Market Entry Barriers and Risks
A. Market Maturity
B. Cost Containment
C. Competition
D. Technological Edge and Limitations
E. Patent Protection
F. Regulatory Constraints
G. Decentralized Testing Market Challenges


VII. Worldwide Market and Technology Overview
A. Cancer Statistics and Etiology
1. Breast Cancer
2. Lung Cancer
3. Colon and Rectum Cancer
4. Prostate Cancer
5. Stomach Cancer
6. Leukemia
7. Lymphoma
8. Oral Cancer
9. Skin Cancer
10. Uterine Cancer
11. Ovarian Cancer
12. Bladder Cancer
B. Major Current And Emerging Cancer Diagnostic Tests
1. Introduction
2. Tumor Marker Classification
3. ACTH
4. Alpha-Fetoprotein (AFP)
5. Beta-2 Microglobulin
6. CA 15-3/27.29
7. CA 19-9
8. CA-125
9. Calcitonin
10. Carcinoembrionic Antigen (CEA)
11. Estrogen and Progesterone Receptors
12. Ferritin
13. Gastrin
14. Human Chorionic Gonadotropin (HCG)
15. Insulin
16. NSE
17. Occult Blood
18. PAP Smear/HPV
19. Prostatic Acid Phosphatase (PAP)
20. Prostate-Specific Antigen (PSA)
21. Squamous Cell Carcinoma Antigen (SCC)
22. T and B Lymphocytes

23. TdT
24. Thyroglobulin
25. Tissue Polypeptide Antigen (TPA)
26. Biochemical Tumor Markers
27. Oncogenes
- Abl/abl-bcr
- AIB1
- BCL-2
- BRCA1
- CD44
- C-fos
- C-myb
- C-myc
- CYP-17
- Erb-B
- HPC1
- N-myc
- P40
- P51
- P53
- PIK3CA
- PTI-1
- Ras
- Reg
- Sis
- Src
28. Polypeptide Growth Factors
- Basic Fibroblast Growth Factor
- Beta-TGF
- Cachectin (TNT)
- Calmodulin
- ECFR
- Nerve Growth Factor (NGF)
- Epidermal Growth Factor (EGF)
- Ornithine Decarboxylase
- Transferrin
- Transforming Growth Factor-Alpha


29. Ectopic Hormones
30. Colony Stimulating Factors
31. Lymphokines
- Alpha-Interferon
- B Cell Growth Factors
- B Cell Growth Factor (BCGF)
- Gamma-Interferon
- Interleukin-1 (IL-1)
- Macrophage Activating Factor
32. Immunohistochemical Stains
33. Emerging Tumor Markers
- N-Acetylglucosamine
- Actin
- Alpha-Actin
- Antineuronal Antibodies
- 7B2
- B72.3
- Bax
- BCD-F9
- BLCA-4
- Blood Group Antigens A,B,H
- CA 50
- CA 72-4/TAG-72
- CA 195
- CA-242
- CA-549
- CAM 26
- CAR-3
- Cathepsin-D
- Chromogranin A and B
- Cluster 1 Antigen
- Cluster-5/5A Antigen
- CTA
- CU18
- DR-70
- DU-PAN-2
- Endometrial Bleeding Associated Factor
- Endostatin
- Epithelial Membrane Antigen
- Feulgen Hydrolysis
- Fibronectin

- FSH
- (1->3)-L-fucosyltransferase
- Gastrin-Releasing Peptide (GRP)
- GDCFP-15
- Glucagon
- Glycoamines
- H23
- Her-2
- Human Carcinoma Antigen
- HPA
- HSP27
- Intermediate Filaments
- Cytokeratins/CK18/Cyfra 21-1
- Desmin
- Gliofibrillary Acid Protein
- Neurofilaments
- Vimentin
- KA 93
- Kinases
- KP16D3
- LAI
- Leukocyte Common Antigen
- Lewis Antigens
- Lysophosphatidic Acid (LPA)
- Ma 695/Ma 552
- MABDF3
- MAG
- ME1
- Minactivin
- MN/CA9
- MSA
- Mucin Cancer Antigen (MCA)
- Multiple Tumor Suppressor 1
- Myosin
- NEA-130
- NMP22
- OA-519
- Opioid Peptides
- P-glycoprotein
- Pancreatic Oncofetal Antigen (POA)
- Placental Lactogen
- PR92

- Proliferative Index, Ki-67
- Px
- RB Inactivation/Deletion
- Ret
- SCCL 175
- Selectin
- Sialic Acid
- Sialyl SSEA-1/SLX
- SN10
- Somatostatin
- TA-90
- TABA
- Tachykinin
- TAG 12
- TPS
- Troponin
- Tubulin
- VCAM
- VEGF
- Villen
C. Cancer Diagnostic Testing Instrumentation Review and Market Needs
D. Current and Emerging Cancer Diagnostic Technologies
1. Monoclonal and Polyclonal Antibodies
2. Immunoassays
3. Molecular Diagnostics
4. Chromosome Analysis
a. Chronic Myelogenous Leukemia (CML)
b. Acute Myeloid Leukemia (AML)
c. Acute Lymphoblastic Leukemia (ALL)
d. Malignant Lymphomas Lymphoid Malignancies
e. Chronic Lymphocytic Leukemia (CLL)
f. Solid Cancers
g. Chromosomal Translocation and Oncogenes
5. Artificial Intelligence
6. Flow Cytometry
7. Two Dimensional Gel Electrophoresis (2-DGE)
8. Biosensors
9. Competing/Complementing Technologies
E. Personal Testing

VIII. UK Cancer Diagnostics Market
A. Executive Summary
B. Business Environment
C. Market Structure
D. Market Size, Test Volume and Sales Forecasts by Market Segment,
Major Supplier Sales and Market Shares by Test
IX. Competitive Profiles
- Abbott
- AdnaGen/Alere
- Agilent Technologies
- Applied Gene Technologies
- Arca Biopharma
- Beckman Coulter/Danaher
- Becton Dickinson
- Biomedical Diagnostics
- bioMerieux
- Bio-Rad
- CellSearch
- Cepheid
- Correlogic Systems/Vermillion
- Decode Genetics
- Diadexus
- Diagnocure
- Diasorin
- Eiken Chemical
- Elitech Group
- Enterix
- Enzo Biochem
- Epigenomics
- Exact Sciences
- Fujirebio
- Guided Therapeutics
- Hologic/Gen-Probe
- Kreatech/Leica
- Kyowa Medex
- Mackay Life Sciences
- Myriad Genetics
- OncoLab

- Ortho-Clinical Diagnostics
- Panacea Pharmaceuticals
- Polartechnics
- Polymedco
- PreMD
- Qiagen
- Quest Diagnostics
- Radient Pharmaceuticals
- Roche
- Scienion
- Sequenom
- Siemens Healthcare
- Takara Bio
- Targeted Diagnostics & Therapeutics
- Tosoh
- Thermo
- Veridex
- Wako Pure Chemicals
- Wallac/PE
- Zila

List Of Tables

Tumor Marker Classification
Major Companies Developing or Marketing
ACTH Tests
Major Companies Developing or Marketing
AFP Tests
Major Companies Developing or Marketing
Beta-2 Microglobulin Tests
Major Companies Developing or Marketing
CA 15-3/27.29 Tests
Major Companies Developing or Marketing
CA 19-9 Tests
Major Companies Developing or Marketing
CA 125 Tests
Major Companies Developing or Marketing
Calcitonin Tests
Major Companies Developing or Marketing
CEA Tests
Major Companies Developing or Marketing
Estrogen Receptor Tests
Major Companies Developing or Marketing
Progesterone Receptor Tests
Major Companies Developing or Marketing
Ferritin Tests
Major Companies Developing or Marketing
Gastrin Tests

Major Companies Developing or Marketing
HCG Tests

Major Companies Developing or Marketing
Insulin Tests

Major Companies Developing or Marketing
NSE Tests
Major Companies Developing or Marketing
Occult Blood Tests
Major Companies Developing or Marketing
PAP Smear/HPV Tests
Major Companies Developing or Marketing
PAP Tests
Major Companies Developing or Marketing
PSA Tests
Major Companies Developing or Marketing
Lymphocyte Subclassification Tests
Biochemical Markers Potential Applications
In Cancer Diagnosis
Oncogenes Potential Applications
In Cancer Diagnosis
Major Companies Developing or Marketing
Oncogene Tests
Growth Factors Potential Applications
In Cancer Diagnosis
Colony Stimulating Factors Potential
Applications in Cancer Diagnosis
Lymphokines Potential Applications In Cancer Diagnosis

Immunohistochemical Stains Potential
Applications in Cancer Diagnosis
Executive Summary Table: U.K., Total
Tumor Marker Test Volume and Sales
Forecast by Market Segment
U.K., Estimated Cancer Death Rates
Per 100,000 Population
U.K., Laboratories Performing Tumor
Marker Tests by Market Segment
U.K., Hospital Laboratories Performing
Tumor Marker Tests by Bed Size
U.K., Commercial/Private Laboratories
Performing Tumor Marker Tests by
Annual Test Volume
U.K., Total Tumor Marker Testing Volume
Forecast by Market Segment
U.K., All Market Segments Major
Tumor Marker Test Volume Forecast
U.K., Hospital Laboratories Major
Tumor Marker Test Volume Forecast
by Test
U.K., Commercial/Private Laboratories
Major Tumor Marker Test Volume Forecast
U.K., Total Tumor Marker Sales
Forecast by Market Segment

U.K., All Market Segments Major
Tumor Marker Sales Forecast by Test
U.K., Hospital Laboratories Major
Tumor Marker Sales Forecast by Test

U.K., Commercial/Private Laboratories
Major Tumor Marker Sales Forecast by Test

U.K., ACTH Test Volume and Diagnostics Sales
Forecast by Market Segment
U.K., AFP Test Volume and Diagnostics Sales
Forecast by Market Segment
U.K., Beta-2 Microglobulin Test Volume and
Diagnostics Sales Forecast by Market Segment
U.K., CA 15-3/27.29 Test Volume and
Diagnostics Sales Forecast by Market Segment
U.K., CA 19-9 Test Volume and Diagnostics
Sales Forecast by Market Segment
U.K., CA-125 Test Volume and Diagnostics
Sales Forecast by Market Segment
U.K., Calcitonin Test Volume and
Diagnostics Sales Forecast by Market
Segment
U.K., CEA Test Volume and Diagnostics
Sales Forecast by Market Segment
U.K., Chromogranin Test Volume and Diagnostics
Sales Forecast by Market Segment
U.K., Colon-Specific Antigen Test Volume
And Diagnostics Sales by Market
Segment
U.K., Cytokeratins Test Volume and
Diagnostics Sales Forecast by Market
Segment
U.K., Estrogen Receptor Test Volume and
Diagnostics Sales Forecast by Market
Segment

U.K., Ferritin Test Volume and
Diagnostics Sales Forecast by Market
Segment
U.K., Gastrin Test Volume and Diagnostics
Sales Forecast by Market Segment
U.K., HCG Test Volume and Diagnostics
Sales Forecast by Market Segment
U.K., Insulin Test Volume and Diagnostics
Sales Forecast by Market Segment
U.K., Lymphocyte Subtyping Test Volume and
Diagnostics Sales Forecast by Market
Segment
U.K., NSE Test Volume and Diagnostics
Sales Forecast by Market Segment
U.K., Occult Blood Test Volume and
Diagnostics Sales Forecast by Market
Segment
U.K., Oncogenes Test Volume and
Diagnostics Sales Forecast by Market
Segment
U.K., Pancreatic Oncofetal Antigen
Test Volume and Diagnostics
Sales Forecast by Market Segment
U.K., PAP Smear Test Volume and Diagnostics
Sales Forecast by Market Segment
U.K., Parathyroid Hormone
Test Volume and Diagnostics
Sales Forecast by Market Segment
U.K., Progesterone Receptor
Test Volume and Diagnostics
Sales Forecast by Market Segment

U.K., PAP Test Volume and Diagnostics
Sales Forecast by Market Segment
U.K., PSA Test Volume and Diagnostics
Sales Forecast by Market Segment
U.K., S-100 Protein Test Volume and
Diagnostics Sales Forecast by Market Segment
U.K., Serotonin Test Volume and Diagnostics
Sales Forecast by Market Segment
U.K., Sialic Acid Test Volume and
Diagnostics Sales Forecast by Market Segment
U.K., Squamous Cell Carcinoma Antigen
Test Volume and Diagnostics
Sales Forecast by Market Segment
U.K., TDT Test Volume and Diagnostics
Sales Forecast by Market Segment
U.K., Thymidine Kinase
Test Volume and Diagnostics
Sales Forecast by Market Segment
U.K., Thyroglobulin
Test Volume and Diagnostics
Sales Forecast by Market Segment
U.K., TPA Test Volume and Diagnostics
Sales Forecast by Market Segment

U.K., Total Tumor Marker Sales and
Market Shares Forecast
U.K., CEA Testing Market Diagnostics
Sales by Major Supplier
U.K., PSA Testing Market Diagnostics
Sales by Major Supplier

Global Interventional Cardiology Devices Market (2018-2023)

Global Interventional Cardiology Devices Market (2018-2023) market research report available in single user pdf license with Aarkstore Enterprise at USD 2950

USD 2950 View Report

Global Corporate Wellness Market (2018-2023)

The global corporate wellness market is forecast to expand at a CAGR of 4.95%, and will reach a value of USD 61.95 Bn by 2023. The Report also Provides highest revenue and market share.

USD 2950 View Report

UK Tumor Marker Testing Analyzers and Reagents Market, 2019-2023: Supplier Shares and Sales Segment Forecasts by Product--Competitive Intelligence, Technology and Instrumentation Review, Opportunities for Suppliers

HighlightsComprehensive 575-page analysis of the UK tumor marker testing market.Major issues pertaining to the UK laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant

USD 6800 View Report

UK Tumor Marker Testing Market, 2019-2023: Supplier Shares by Test, and Market Segment Sales Forecasts

This report provides an overview of the U.K. cancer diagnostics market, including market shares of leading suppliers by test, as well as volume and sales forecasts by market segment.Table of

USD 950 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available